Biocon Ltd.

Financial

	Biocon	Concord Biotech	Advanced Enzyme
Operational Metrics
Pharmaceutical Sector
Domestic Sales Growth - YoY	7.7 %	n/a	n/a
R&D as a % of Total Sales	7.0 %	2.3 %	10.41 %
Financials
5 yr Average ROE	5.97 %	19.73 %	10.77 %
5yr average Equity Multiplier	2.64	1.21	1.15
5yr Average Asset Turnover Ratio	0.31	0.54	0.41
5yr Avg Net Profit Margin	7.2 %	30.4 %	22.63 %
Price to Book	2.22	9.45	2.42
P/E	124.79	48.1	25.09
5yr Avg Cash Conversion Cycle	-193.26 Days	76.63 Days	109.31 Days
Inventory Days	102.53 Days	79.03 Days	77.49 Days
Days Receivable	139.43 Days	132.49 Days	61.31 Days
Days Payable	307.82 Days	157.9 Days	49.86 Days
5yr Average Interest Coverage Ratio	8.77	195.92	54.21
5yr Avg ROCE	6.71 %	25.76 %	14.52 %
5yr Avg Operating Profit Margin	19.38 %	43.43 %	35.47 %
5 yr average Debt to Equity	0.75	0.03	0.02
5yr CAGR Net Profit	6.47 %	9.62 %	-2.12 %
5yr Average Return on Assets	2.35 %	16.36 %	9.32 %
Shareholdings
Promoter Holding	54.45 %	44.08 %	43.08 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-6.19 %	0.0	-9.62 %
Change in Mutual Fund Holding (3 Yrs)	12.19 %	-0.9 %	-0.59 %

Business

	Biocon	Concord Biotech	Advanced Enzyme
Product Wise Break-Up	Product Wise Break-Up Biosimilars 61.01 Syngene (Research Services) 21.71 Generics 17.29 Novel 0 Branded Formulations 0 Biologics 0 Formulations 0 API - Fermentation based 0 Specialized Manufacturing 0 Bio-process 0 Animal nutrition 0 Human nutrition 0	Product Wise Break-Up API - Fermentation based 75.39 Biosimilars 0 Syngene (Research Services) 0 Bio-process 0 Animal nutrition 0 Generics 0 Formulations 24.61 Branded Formulations 0 Biologics 0 Human nutrition 0 Specialized Manufacturing 0 Novel 0	Product Wise Break-Up API - Fermentation based 0 Biosimilars 0 Syngene (Research Services) 0 Bio-process 13.0 Animal Health 14.0 Generics 0 Formulations 0 Branded Formulations 0 Biologics 0 Human nutrition 66.0 Specialized Manufacturing 7.0 Novel 0
Location Wise Break-Up	Location Wise Break-Up USA 46.14 Ireland 25.21 Rest of the World 22.24 India 6.4 Asia (Ex India) 0 Europe 0 Others 0.01	Location Wise Break-Up India 59.31 Europe 0 Asia (Ex India) 0 Rest of the World 40.69 Ireland 0 USA 0	Location Wise Break-Up India 53.0 Europe 5.0 Asia Pacific 9.0 Rest of the World 0 Ireland 0 USA 30.0 Others 3.0
Operating Profit Break-Up	Operating Profit Break-Up Others 100	-	-
Asset Break-Up	Asset Break-Up Biosimilars 75.35 Generics 13.4 Research 11.25 Novel Biologics 0 India 0 USA 0 Europe 0	Asset Break-Up India 99.74 Europe 0 Novel Biologics 0 Biosimilars 0 Generics 0 Research 0 USA 0 Others 0.26	Asset Break-Up India 48.73 Europe 8.2 Novel Biologics 0 Biosimilars 0 Generics 0 Research 0 USA 43.08

Biocon Ltd.

SIGN UP FOR FREE